4DMedical Limited (FDMDF) Fair Value & Analysis
Healthcare · US · Market cap $1.6B
4DMedical Limited
FDMDF · US
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 16 days ago
Fair value updated Jun 24, 2026 — revised from $0.3400 to $0.3300 (−2.9%) since Jun 23, 2026. Share price +24.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.1567 – $4.82 · fair‑value band $0.2500 – $0.4200 · the $2.70 price screens above the $0.3300 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
4DMedical Limited (FDMDF) currently trades at $2.70, while our model-based Fair Value estimate is $0.3300 — implying the stock looks roughly 87.8% overvalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $5.8M. Revenue declined 1.5% year over year. The balance sheet holds a net cash position of $2.6M. Fundamentals as of Jun 24, 2026
Our scenario range runs from $0.2500 (bear case) to $0.4200 (bull case); at $2.70, the current price sits above that range. The share trades about 46% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside — at -88%, FDMDF screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging. It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner. The company was incorporated in 2012 and is based in Carlton, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
4DMedical Limited reported revenue of $5.9M in FY2025 versus $217K in FY2021, a compound +127.9%/yr. Reported net income was −$30.1M in FY2025.
Is FDMDF fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,228 MXN | -23% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EW | $87.45 | $41.02 | -53% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| DexCom, Inc DXCM | $74.77 | $53.93 | -28% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 4DMedical Limited (FDMDF) undervalued?
What is the fair value of FDMDF?
What is the quality score of FDMDF?
What is the revenue of 4DMedical Limited (FDMDF)?
What is the net profit margin of FDMDF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
The 25 strongest value stocks, free every month
Enter your email to get the free monthly Top-25 report of the most undervalued quality stocks from 35,000+ analysed. Unsubscribe anytime.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.